Quick Answer
Century Therapeutics, Inc. reported Earnings Per Share Diluted of $0.14 (loss) per share for the year ending 2025.
- Century Therapeutics, Inc. showed an increase of +91.3% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Century Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $1.75 (loss) per share | Q1 2021: $2.39 (loss) per share | Q2 2021: $1.93 (loss) per share | Q3 2021: $0.48 (loss) per share | Q1 2022: $0.66 (loss) per share | Q2 2022: $0.54 (loss) per share | Q3 2022: $0.53 (loss) per share | Q1 2023: $0.53 (loss) per share | Q2 2023: $0.56 (loss) per share | Q3 2023: $0.55 (loss) per share | Q1 2024: $0.45 (loss) per share | Q2 2024: $0.38 (loss) per share | Q3 2024: $0.37 (loss) per share | Q1 2025: $0.89 per share | Q2 2025: $0.38 (loss) per share | Q3 2025: $0.40 (loss) per share.
- Over the full 6 years of available data (2020 to 2025), Century Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 98.0%.
- Historical annual values: Fiscal year 2025: $0.14 (loss) per share | Fiscal year 2024: $1.61 (loss) per share | Fiscal year 2023: $2.30 (loss) per share | Fiscal year 2022: $2.96 (loss) per share | Fiscal year 2021: $2.96 (loss) per share | Fiscal year 2020: $7.16 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: